Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Top-Five UPGRADES From

|Includes: AMAG Pharmaceuticals, Inc. (AMAG), EBS, IMKTA, NLNK, USCR

VALUATION WATCH: Overvalued stocks now make up 37.57% of our stocks assigned a valuation and 12.51% of those equities are calculated to be overvalued by 20% or more. Three sectors are calculated to be overvalued.


----ValuEngine Top-Five UPGRADES for the Day

ValuEngine tracks more than 7000 US equities, ADRs, and foreign stock which trade on US exchanges as well as @1000 Canadian equities. When EPS estimates are available for a given equity, our model calculates a level of mispricing or valuation percentage for that equity based on earnings estimates and what the stock should be worth if the market were totally rational and efficient--an academic exercise to be sure, but one which allows for useful comparisons between equities, sectors, and industries. Using our Valuation Model, we can currently assign a VE valuation calculation to more than 2800 stocks in our US Universe.

We also use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database. Our Buy/Sell/Hold recommendations are based upon the 1-year forecast return figure. Using valuation and forecast figures, you can rank and rate our covered stocks against each other, to find out, in an objective and systematic way, the most attractive investment targets based on your own risk/reward parameters. We re-calculate the entire database every trading day, so you are assured that every proprietary valuation and forecast datapoint is as up-to-date as possible.

Below, we present the latest top-five list of UPGRADED stocks from our models. They presented alphabetically. US Concrete is the top pick.







Ticker Company Name Market Price Valuation Last 12-M Return 1-M Forecast Return 1-Yr Forecast Return P/E Ratio Sector Name
AMAG AMAG PHARMA INC 43.73 -7.46% 91.97% 1.09% 13.15% 16.26 Medical
EBS EMERGENT BIOSOL 29.43 -10.19% 37.20% 0.54% 6.50% 24.39 Medical
IMKTA INGLES MARKET A 44.34 -3.23% 85.37% 1.10% 13.17% 15.37 Retail-Wholesale
NLNK NEWLINK GENETIC 48.15 6.20% 100.71% 1.09% 13.11% 13.82 Medical
USCR US CONCRETE INC 46.18 N/A 80.25% 1.12% 13.43% 16.28 Construction

Below is today's data on USCR:

U.S. Concrete Inc. (NASDAQ:USCR) operates as a provider of ready-mixed concrete and concrete-related products and services to the construction industry in the United States. The Company operates in two segments: ready-mixed concrete and concrete-related products; and precast concrete. The Company's ready-mixed concrete and concrete-related products segment produces and sells ready-mixed concrete, aggregates (crushed stone, sand and gravel), concrete masonry and building materials. Its precast concrete products segment produces and sells precast concrete products. Markets served by the Company include west Texas, northern California, New Jersey, New York, Washington, D.C., Oklahoma and the mid-Atlantic region. U.S. Concrete Inc. is based in Houston, Texas, USA.

VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from BUY to STRONG BUY for US CONCRETE INC on 2015-09-25. Based on the information we have gathered and our resulting research, we feel that US CONCRETE INC has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE Momentum and Sharpe Ratio.

You can download a free copy of detailed report on USCR from the link below.


ValuEngine Forecast
1-Month 13.90 1.00%
3-Month 14.14 2.80%
6-Month 14.44 4.97%
1-Year 15.40 11.94%
2-Year 15.41 12.00%
3-Year 12.71 -7.62%


Valuation & Rankings
Valuation n/a Valuation Rank(?) n/a
1-M Forecast Return 1.12% 1-M Forecast Return Rank 99
12-M Return 80.25% Momentum Rank(?) 97
Sharpe Ratio 0.83 Sharpe Ratio Rank(?) 91
5-Y Avg Annual Return 38.79% 5-Y Avg Annual Rtn Rank 98
Volatility 46.67% Volatility Rank(?) 38
Expected EPS Growth 13.98% EPSGrowth Rank(?) 50
Market Cap (billions) 0.65 Size Rank 61
Trailing P/E Ratio 16.28 Trailing P/E Rank(?) 67
Forward P/E Ratio 14.28 Forward P/E Ratio Rank 55
PEG Ratio 1.16 PEG Ratio Rank 36
Price/Sales 0.81 Price/Sales Rank(?) 70
Market/Book 5.55 Market/Book Rank(?) 21
Beta 1.41 Beta Rank 25
Alpha 0.73 Alpha Rank 98